STOCK TITAN
  1. Home
  2. News
  3. CTMX

CytomX Therapeutics Inc - CTMX STOCK NEWS

Welcome to our dedicated news page for CytomX Therapeutics (Ticker: CTMX), a resource for investors and traders seeking the latest updates and insights on CytomX Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CytomX Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CytomX Therapeutics's position in the market.

News
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors
Rhea-AI Summary
CytomX Therapeutics, Inc. announced the dosing of the first patient in a Phase 1 study of CX-2051, a promising antibody drug conjugate for solid tumors. The drug targets EpCAM, a common cancer marker, and utilizes a potent cytotoxic payload. The study aims to assess safety and efficacy, with potential dose expansions in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Rhea-AI Summary
CytomX Therapeutics, Inc. achieves a second clinical candidate nomination under the TCB collaboration with Astellas, triggering a $5 million milestone payment. The collaboration focuses on conditionally activated TCB programs, with CytomX retaining US co-commercialization and economic rights for select programs. Both companies express excitement about the potential of T-cell engaging bispecifics in treating solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
News
CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors
Rhea-AI Summary
CytomX Therapeutics, Inc. appoints Dr. Zhen Su, an experienced physician executive, to its board of directors. Dr. Su's extensive background in oncology research and development will contribute to shaping the company's strategy and advancing its multi-modality PROBODY® therapeutic pipeline. His appointment reflects CytomX's commitment to developing safer and more effective therapies for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
management
News
CytomX Therapeutics Announces Milestone Achievement in PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
Rhea-AI Summary
CytomX Therapeutics initiates GLP toxicology study triggering a $5 million milestone payment from Astellas for the first clinical candidate in their collaboration. The program is part of a larger alliance focusing on T-cell engaging bispecifics, with CytomX retaining US co-commercialization rights for certain programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
-
News
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
Rhea-AI Summary
CytomX Therapeutics, Inc. (Nasdaq: CTMX) reported full year 2023 financial results and provided a business update. Key highlights include progress in Phase 1 clinical studies for CX-904, CX-2051, and CX-801 targeting solid tumors. The company also announced a strategic collaboration with Amgen and FDA allowance for CX-2051 IND application. Financially, CytomX maintained a strong position with $174.5 million in cash and investments as of December 31, 2023, driven by revenue growth and cost control measures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.34%
Tags
earnings
-
News
CytomX Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
Rhea-AI Summary
CytomX Therapeutics, Inc. (CTMX) will report its full year 2023 financial results on March 11, 2024, after the U.S. markets close. A conference call and webcast will follow the announcement. Participants can access the live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
conferences earnings
News
CytomX Therapeutics to Present at Upcoming March Investor Conferences
Rhea-AI Summary
CytomX Therapeutics, Inc. (CTMX) will participate in investor conferences in March 2024, including TD Cowen's 44th Annual Health Care Conference and Barclays 26th Annual Global Healthcare Conference. Live webcasts of the presentations will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.36%
Tags
conferences
-
News
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
Rhea-AI Summary
CytomX Therapeutics, Inc. has received FDA clearance for its Investigational New Drug applications for CX-2051 and CX-801, anticipating the initiation of Phase 1 clinical studies in the first half of 2024. These Probody® therapeutics have the potential to address major unmet needs in oncology and are designed to target EpCAM-positive tumors and solid tumors including melanoma, renal, and head and neck squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.97%
Tags
clinical trial
-
News
CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference
Rhea-AI Summary
CytomX Therapeutics, Inc. (Nasdaq: CTMX) CEO Sean McCarthy to participate in fireside chat at B. Riley Securities Virtual Annual Oncology Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.37%
Tags
conferences
News
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
Rhea-AI Summary
CytomX Therapeutics, Inc. (Nasdaq: CTMX) announced its 2024 company priorities and anticipated milestones for its wholly-owned and partnered pipeline. The company is well-positioned with multiple IND applications filed and a broad pipeline progress anticipated within research and development partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.91%
Tags
none
Stock CTMX logo
CytomX Therapeutics Inc

Nasdaq:CTMX

CTMX Rankings

#4120 Ranked by Market Cap
#3224 Ranked by Stock Gains
N/A Ranked by Dividends

CTMX Stock Data

145.62M
53.82M
1.19%
48.6%
4.91%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South San Francisco

About CTMX

cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o